News

b

b

Current News in Drug Discovery

RSS Nature Reviews Drug Discovery
  • The Biomarkers Consortium: 20 years of advancing precision medicine January 29, 2026
    Nature Reviews Drug Discovery, Published online: 29 January 2026; doi:10.1038/d41573-025-00187-8The Foundation for the National Institutes of Health Biomarkers Consortium is celebrating two decades of advancing biomarker science to enable earlier interventions, personalized medicine and improved outcomes in disease prevention, detection, diagnosis and treatment.
    Amanda Klein
  • Hunting for biopharma’s innovation sweet spot January 28, 2026
    Nature Reviews Drug Discovery, Published online: 28 January 2026; doi:10.1038/d41573-026-00011-xWilliam Pao — a former chief development officer at Pfizer and head of Roche pharma research and early development — discusses his book Breakthrough, about biopharmaceutical innovation.
    Asher Mullard
  • Strategies for blood–brain barrier rejuvenation and repair January 28, 2026
    Nature Reviews Drug Discovery, Published online: 28 January 2026; doi:10.1038/s41573-025-01364-5The blood–brain barrier (BBB) is a dynamic interface that tightly regulates the transport of substances from the blood into the brain. BBB dysfunction can occur with ageing and is a hallmark of many major diseases but is underappreciated as a therapeutic target. Here, Searson and Banks […]
    Peter C. Searson
  • Roads and detours for CAR T cell therapy in autoimmune diseases January 26, 2026
    Nature Reviews Drug Discovery, Published online: 26 January 2026; doi:10.1038/s41573-025-01349-4Following on from its success in eradicating malignant B cells in cancer, chimeric antigen receptor (CAR) T cell therapy has been extended to treat autoimmune diseases. This Review discusses the preclinical studies and ongoing clinical trials of CAR T cells in autoimmune disorders, highlighting future opportunities […]
    Jérôme Avouac
  • Biopharma dealmaking in 2025 January 21, 2026
    Nature Reviews Drug Discovery, Published online: 21 January 2026; doi:10.1038/d41573-026-00013-9Biopharma dealmaking in 2025
    Patricia Giglio
  • 2025 FDA approvals: volume maintained, but value remains below average January 20, 2026
    Nature Reviews Drug Discovery, Published online: 20 January 2026; doi:10.1038/d41573-026-00012-w2025 FDA approvals: volume maintained, but value remains below average
    Mathias Baedeker
  • Redirecting mast cells for antigen-specific cancer immunotherapy January 14, 2026
    Nature Reviews Drug Discovery, Published online: 14 January 2026; doi:10.1038/d41573-026-00008-6Redirecting mast cells for antigen-specific cancer immunotherapy
    M. Teresa Villanueva
  • Lilly pays US$1.2 billion for Ventyx and its oral anti-inflammatories January 14, 2026
    Nature Reviews Drug Discovery, Published online: 14 January 2026; doi:10.1038/d41573-026-00009-5Lilly pays US$1.2 billion for Ventyx and its oral anti-inflammatories
    Asher Mullard

Vitreon America™ Launches Botanicopeia™ Database and Federal Government Services at NIH Festival+

 BETHESDA, MD, September 17, 2016 − Vitreon America, Inc.™ participated this week in the National Institute of Health (NIH) Intramural Research Program’s 30th Annual NIH Research Festival which was held September 15-16, 2016 at the NIH Bethesda, Maryland campus.

The Festival included plenary sessions, symposia, exhibits, poster sessions and tours designed to encourage sharing and learning about the exciting research taking place on NIH campus.

Vitreon America™ was selected by the Technical Sales Association (TSA) which sponsors the Research Festival Exhibit, to launch its state-of-the-art Phytochemical and Ethnobotanical database subscription services, Botanicopeia™.

Attending on behalf of Vitreon America™
were Michael Megginson, VP of Business Development (left) and Jorgen Sandberg,
CEO (right).

Vitreon America was pleased to see the interest from the NIH Institutions to utilize the Botanicopeia™ database subscriptions with many NIH researchers expressing interest in considering the Vitreon America Botanical Research Analytic services as well to optimize the Botanicopeia™ database.

Based on the NIH researchers feedback, Vitreon America has established a Botanicopeia™ database subscription service agreement and subscription service with botanical research analytic services through Marshall Communications Corporation, www.marshallcomm.com.

Vitreon America services are available through Marshall Communications Corporation (VOSB) on NIH’s Information Technology Acquisition and Assessment Center’s (NITAAC)- Government-wide Acquisition Contract (GWAC) vehicle. [Prime Contract Holder #HHSN316201500063W]

Vitreon America™ was established with the goal of commercializing their Botanicopeia™ database and botanical research analytic services for development of botanicals and phytochemicals in the creation of new medicinal products by Vitreon America Clients.

To find out more about our Services please contact us for assistance at 1-888-214-2584 or at info@vitreonamerica.com

About Vitreon America™

Vitreon AmericaTM was formed with the goal of disseminating their BotanicopeiaTM database to encourage the increased use of botanicals and phytochemicals in the creation of new medicines.

Contact Vitreon America, Inc.

Vitreon America Botanical Research Center @ Hopkins Johns Hopkins University

MCC 9601 Medical Center Drive, Suite 221
Rockville, Maryland 20850

+1-888-214-2584

j.shaver@advasur.com